Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

@inproceedings{Sundlv2017Individualised1T,
  title={Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry},
  author={Anna Sundl{\"o}v and Katarina Sj{\"o}green-Gleisner and Johanna Svensson and Michael Ljungberg and Tomas G Olsson and P Bernhardt and Jan G Tennvall},
  booktitle={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2017}
}
To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED). Treatment was given with repeated cycles of 7.4 GBq 177Lu-DOTATATE at 8-12-week intervals. Detailed dosimetry was performed in all patients after each cycle using a hybrid method (SPECT + planar imaging). All patients received… CONTINUE READING